menu
    • menu

    Company profile for Tr1X Bio

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tr1X Inc. is a biotech firm focused on pioneering cellular immunotherapies for autoimmune and inflammatory conditions. Leveraging its proprietary platform, the company aims to create groundbreaking cell therapy products designed to rebalance the immune system and foster long-term tolerance. Headquartered in La Jolla, CA, Tr1X aspires to lead the global development of Tr1-based immunotherapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tr1X BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Suite 500 San Diego, CA 92121
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tr1x.bio/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tr1x/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tr1X Gets FDA IND Clearance For TRX319, In Progressive MS
    Tr1X Gets FDA IND Clearance For TRX319, In Progressive MS

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3166144/0/en/Tr1X-Announces-FDA-Clearance-of-IND-Application-for-TRX319-a-First-in-Class-Allogeneic-CAR-Tr1-Treg-Cell-Therapy-for-Progressive-Multiple-Sclerosis-and-50-Million-in-Additional-Fin.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share
    Tr1X gets $8M CIRM grant for TRX103 Phase 1/2a trial
    Tr1X gets $8M CIRM grant for TRX103 Phase 1/2a trial

    04 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/04/3055913/0/en/Tr1X-Awarded-8-Million-CIRM-Grant-to-Support-TRX103-Phase-1-2a-Clinical-Trial-for-Graft-Versus-Host-Disease.html

    GLOBENEWSWIRE
    04 Apr 2025
    Share Share
    Tr1X Appoints David de Vries CEO, Effective June 1
    Tr1X Appoints David de Vries CEO, Effective June 1

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051323/0/en/Tr1X-Announces-Succession-Plan-Appoints-David-de-Vries-CEO-Effective-June-1-Bill-Lis-to-Serve-as-Executive-Chairman.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    Tr1X Receives FDA Clearance For TRX103 IND In Crohn's Disease
    Tr1X Receives FDA Clearance For TRX103 IND In Crohn's Disease

    07 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/07/2925903/0/en/Tr1X-Announces-FDA-Clearance-of-IND-Application-for-TRX103-an-Allogeneic-Engineered-Tr1-Treg-Cell-Therapy-for-Treatment-Refractory-Crohn-s-Disease.html

    GLOBENEWSWIRE
    07 Aug 2024
    Share Share
    Tr1X Doses First Patient In GvHD Trial Of TRX103 Tr1 Cell Therapy
    Tr1X Doses First Patient In GvHD Trial Of TRX103 Tr1 Cell Therapy

    10 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/10/2911048/0/en/Tr1X-Announces-First-Patient-Dosed-in-Proof-of-Concept-GvHD-Trial-Evaluating-TRX103-a-First-in-Class-Type-1-Treg-Tr1-Cell-Therapy.html

    GLOBENEWSWIRE
    10 Jul 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search